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Carrier screening is the practice of testing individuals to identify those at increased risks of
having children affected by genetic diseases. Professional guidelines on carrier screening
have been available for more than 15 years, and have historically targeted speciﬁc diseases
that occur at increased frequencies in deﬁned ethnic populations. Enabled by rapidly
evolving technology, expanded carrier screening aims to identify carriers for a broader
array of diseases and may be applied universally (equally across all ethnic groups). This
new approach deviates from the well-established criteria for screening models. In this
review, we summarize the rationale for expanded carrier screening using available
literature regarding clinical and technical data, as well as provider perspectives. We also
discuss important avenues for further research in this burgeoning ﬁeld.
& 2016 The Authors. Published by Elsevier Inc. This is an open access article under the CC
BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).Introduction
Rapid changes in genomic analytic technologies now enable
new implementations of carrier screening, the practice of
screening individuals or couples in order to identify those
with the highest odds of conceiving children affected by
genetic disease. Like the traditional carrier screening practice
discussed by Wick and Rose in this journal issue, the newer
approach also targets autosomal or X-linked recessive dis-
eases that primarily affect newborns and children by causing
cognitive and physical disability and/or shortened life span.
Both approaches share the same objective—to inform couples
of their risks so that they may consider reproductive options.
Where the approaches differ are in the number and types
(including inheritance, severity, and treatability) of diseases
screened and the individuals to whom they are offered. Carrier
screening has historically assessed a relatively small number
of diseases selected based on similar characteristics—high5
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molecular diagnostics lab
A. Lazarin).frequency in a certain subpopulation and association with
severe morbidity or mortality. Now, “expanded carrier screen-
ing” (ECS) is the practice of screening all individuals for dozens
to hundreds of diseases, some with lower frequencies or
severity grades, typically without tailoring to a person’s
reported ethnicity.
Widespread ECS is achievable only because new technolo-
gies have dramatically increased the amount of genomic area
that can be analyzed at a reasonable cost. These same
advances have enabled other genomic tests, such as whole-
exome- and whole-genome sequencing, that may be used in
a diagnostic setting. In contrast to those, ECS is targeted at
diseases already described in the medical literature and
recognized by medical geneticists. As such, ECS represents
the recognition of the newfound practicality of screening
a large number of known diseases, rather than a protocol
for discovery of novel diseases or genotype–phenotype
correlations.pen access article under the CC BY-NC-ND license
oratory that performs expanded carrier screening.
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carrier screening as well as its current landscape, including
professional organization statements, provider perspectives,
published laboratory and clinical data, and counseling con-
siderations. Given its relative infancy, signiﬁcant contribu-
tions to the medical literature on ECS will continue to accrue
rapidly. Consequently, we conclude the article by highlight-
ing the most prominent knowledge gaps, and suggest direc-
tions for future work.Rationale for ECS
As described above, ECS encompasses two components that
are departures from long-standing screening protocols: a
larger list of diseases coupled to pan-ethnic application. In
the context of decreasing costs for genomic analysis, we will
expand on each of these components.
The reasons for ethnicity-driven screening protocols in the
United States (US) are described in the previous article by
Wick and Rose. However, pan-ethnic or universal screening
for two diseases, cystic ﬁbrosis and spinal muscular atrophy,
has been recommended by the American College of Obstetri-
cians and Gynecologists1 (ACOG) and/or the American College
of Medical Genetics and Genomics2,3 (ACMG). In the case of
spinal muscular atrophy, ACMG considered the relatively
high prevalence in all ethnic groups (though there has since
been data that establishes some inter-ethnic variability,
ACMG nonetheless reafﬁrmed its position in 2013). In con-
trast, cystic ﬁbrosis demonstrates wide ethnic disparity in its
prevalence. Screening guidelines for cystic ﬁbrosis originally
targeted Caucasians and Ashkenazi Jewish (AJ)4 populations.
However, in 2005 ACOG updated its recommendation to
justify pan-ethnic screening as “it is becoming increasingly
difﬁcult to assign a single ethnicity to individuals.”1 Ross5
extended this reasoning to hemoglobinopathies and other
diseases screened in targeted populations, calling for equi-
table access to reproductive information.
Recent demographic changes in the US have created
challenges to reliable ethnic identiﬁcation, consequently
leading to increased likelihood of disease occurrence in
non-targeted groups. For example, up to 12% of infants
diagnosed with a beta-hemoglobinopathy via newborn
blood-spot analysis in California during the early 1990s were
outside of the groups included in ACOG’s carrier screening
guideline.6 Such demographic changes are sure to continue,
indicating that pan-ethnic carrier screening will improve
detection of at-risk couples. The 2010 Census shows sub-
stantial increases in individuals reporting mixed racial ances-
try, especially among those of reproductive age and younger.7
Similarly, the Jewish intermarriage rate is currently 48%,8
assuring that diseases currently screened in the AJ popula-
tion will persist in other groups, as has occurred with Tay–
Sachs disease.9 The shift to pan-ethnic offering of any
disorder screened can be summarized most simply as an
equitable, effective model for an evolving population.
In addition to removing ethnicity considerations, the ECS
model also proposes expanding the list of diseases identiﬁed
in routine carrier screening. Current guidelines stipulate
screening only for cystic ﬁbrosis, spinal muscular atrophy,and/or hemoglobinopathies in the largest U.S. subpopula-
tions.1,3,10 Tay-Sachs disease screening is offered to individ-
uals of Cajun or French Canadian ancestry.11 Individuals of AJ
ancestry may be offered screening for an additional three or
eight diseases, depending on the professional guideline that
is followed.11,12 While screening guidelines already enumer-
ate more diseases in AJ individuals than in any other
population, addition of even more diseases has occurred.
Scott et al.,13 assessed acceptability, uptake and results of
screening for 16 disorders in the New York-based AJ popula-
tion, ﬁnding it to be feasible and acceptable. An at-home
testing model for 19 diseases in the AJ population is being
evaluated on an ongoing basis,14 and a comparison of six
laboratories found “AJ panels” of up to 25 diseases.15 While
screening criteria have typically focused on the most severe
diseases with carrier frequencies exceeding 1%, these panels
depart from strict adherence by including diseases that
have variable or milder expressivity (e.g., Gaucher disease),
or lower carrier frequencies (e.g., NEB-related nemaline
myopathy). ECS is well underway in the AJ population.
Considering an expanded disease list in all populations is
reasonable when noting that Mendelian diseases account for
20% of infant mortality and 18% of infant hospitalizations in
the US.16
Many public health and individual beneﬁts of ECS were
proposed by Kingsmore, including greater availability and
utilization of treatments and preventions, diagnostic cost and
time reduction, quality of life improvement, and decrease of
unnecessary treatments, among others.16 There are few
“common” inherited diseases (of a frequency comparable to
sickle cell disease, alpha-thalassemia, and cystic ﬁbrosis), but
the collective incidence of “rare” diseases surpasses the
incidence of those common ones.17 Since population screen-
ing has consistently resulted in reduced incidence of the
diseases of interest,18,19 it is reasonable to assume that large-
scale ECS implementation would likewise impact a larger
portion of related mortality and morbidity.
The increasing number of expanded carrier screens per-
formed in recent years has enabled more objective estima-
tions of carrier frequencies and associated risk, including
those of rare diseases. For instance, data from a large multi-
ethnic population showed that the risk of a collective group
of 89 diseases exceeded that of open neural tube defects or
trisomy 21 pregnancy for a 20-year-old woman.20 Since the
prevalence of trisomy 21 and open neural tube defects has
been used to justify universal screening for these disor-
ders,21,22 and since recessive disease prevalence is likewise
typically cited as an important criterion for screening,12
similar data for rare disease raise consideration for popula-
tion-based implementation.
Beyond reproductive decision-making, an expanded dis-
ease panel may also widen the scope of objectives that can be
achieved through carrier screening. There has been reliance
on newborn screening to detect recessive diseases postna-
tally where early interventions result in improved outcomes.
Prenatal awareness of substantial risk may confer even
greater beneﬁts, since certain diseases (e.g., medium chain
acyl-CoA dehydrogenase deﬁciency) may cause long-term
sequelae even before newborn screening results are available,
or may be diagnosed at ages by which another affected
Box–Principles of pre-test counseling.
Carrier screening identifies couples who may conceive an at-risk pregnancy/birth.There are three overarching groups of
anomalies: inherited genetic diseases (e.g., cystic fibrosis), sporadic genetic diseases (e.g., Down syndrome), and
diseases without obvious cause (e.g., spina bifida). Carrier screening addresses the first group.
Family history does not usually indicate risk for these diseases.
The diseases tested range in their presentations: cognitive disability, physical impairment, shortened lifespan, or some
combination of these.
In most cases, both partners must be carriers for the same disease in order to have an increased risk of an affected
offspring. While it is common to be identified as a carrier for one disease, it is uncommon for both partners to carry
the same disease. If found to be a carrier, the usual next step is to test the partner for the same disease.
When both partners are carriers of the same disease, next steps to consider are prenatal diagnosis via amniocentesis or
chorionic villus sampling, or preconception options, such as preimplantation genetic diagnosis, gamete donors, or
adoption.
Typically, individuals do not experience any symptoms of the diseases they carry. However, it is possible for carrier
screening to reveal personal health effects. Once testing is completed, if applicable, specific disease details and all
implications will be discussed. Genetic counseling should be made available.
No testing addresses all possible birth defects and diseases. Carrier screening, and other available tests and ultrasounds,
identify many of the most common conditions.
Adapted from Edwards et al.,27 Grody et al.,26 and Elias and Annas.43
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carrier status of certain diseases may also raise aware-
ness of maternal obstetric complications and affect
management.25
In summary, carrier screening can be expanded in multiple
ways with beneﬁts to each: more individuals, resulting in
equitable application of genomic technology; more diseases
to better address the spectrum of genetic disease; and more
objectives, i.e., to not only avert affected births, but also to
improve neonatal/pediatric treatments and reduce maternal
morbidity.Professional society statements on expanded
carrier screening
The ACMG issued the ﬁrst position statement on ECS, which
primarily addressed criteria for disease inclusion on an ECS
panel.26 Among these were the recommendations that phe-
notypes should warrant consideration of prenatal diagnosis,
and that the genes and speciﬁc mutations associated with the
diseases should be well understood in order to assess risk.
Where diseases vary in severity or presentation (including
those with onset in adulthood), patients should be made
aware of and consented to be screened for such. It also brieﬂy
addresses pre- and post-test education and counseling con-
siderations, including the need for a generic rather than
disease speciﬁc consent approach and indications for formal
genetic counseling.
This year, a comprehensive “Points to Consider” document
was jointly issued by the ACOG, ACMG, Society for Maternal-
Fetal Medicine, National Society of Genetic Counselors, and
Perinatal Quality Foundation.27 It also addresses the pheno-
typic and molecular characteristics of diseases to be tested,
and further expands on pre-test consent and post-test man-
agement. Based on these statements, and on generic
informed consent model put forth by Elias and Annas28; Boxdescribes an example of pre-test discussion. A recent survey
found most individuals preferred more detailed, rather than
briefer, generic consent models, and a sizable minority
indicated the opposite.29 More thorough study of patients’
pre-test needs is warranted, since this study’s conclusions
may not be generalizable.
Post-test, formal genetic counseling is indicated when an
at-risk couple (having a 25% chance of an affected child) is
identiﬁed. In other cases, post-test education and counseling
centers on carriers and includes a discussion of residual risks
and alternative testing options for the partner, including
sequence analysis or enzymatic studies.
Lastly, in recognition of ECS adoption outside the US, the
European Society of Human Genetics will also be issuing
guidelines for responsible implementation. In addition to
reviewing ECS in the context of carrier screening that has
been performed to varying degrees in Europe, the draft also
covers clinical and counseling considerations, and cautions
about diseases or mutations that have milder expressivity
and do not affect reproductive decision making.30
None of these publications indicate preference for ECS over
traditional screening protocols, but do acknowledge its bene-
ﬁts, increasing utilization, and put forth justiﬁable ways for it
to be implemented, at the discretion of the individual
physician.Testing experience
Analytical performance
Overall, two primary approaches to expanded carrier screen-
ing exist: targeted analysis of pre-selected mutations known
to have valid associations with a particular disease (i.e.,
targeted genotyping) or sequence analysis via next-genera-
tion methodologies. The latter method detects a broader
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or no pathogenic effects.
Though sequence analysis is becoming more prominently
available, most U.S.-based commercial laboratories currently
use the former approach. Results from a published validation
study comparing a microarray-based platform assessing 454
variants causing 105 diseases to single-gene based methods,
found similar analytical performance.17 This method was
further found to have 100% concordance with a clinical
population of known carriers.31
Next-generation sequencing (NGS) promises high clinical sen-
sitivity in assayed genes, though issues of variant interpretation
are considerable. Bell et al.,32 found high analytic sensitivity and
speciﬁcity using an NGS approach for 448 recessive diseases.
Clinical experience
The only clinical data on ECS published to date compiled
results from targeted-genotyping based screening of a multi-
ethnic U.S. population of 23,453 individuals. Approximately one
in four individuals carried at least one disease and 69–77% of
these carriers were not included in guidelines issued by ACMG
or ACOG. In addition, carriers of diseases traditionally screened
in certain ethnic subpopulations were found to be present
in individuals of other ethnicities.33 Ethnic-speciﬁc carrier
frequencies were reported for the ﬁrst time for many diseases.
NGS data has been published recently after carrier assess-
ment for a small number of genes. Greater numbers of
carriers per gene were identiﬁed, as expected. In 11,691
individuals screened by NGS for 15 genes, approximately one-
quarter carried mutations not typically included in targeted
panels.34 When assaying CFTR mutations by NGS, Lim et al.35
concluded that current genotyping panels underperform in
minority populations, particularly South and East Asians. Cystic
ﬁbrosis is already recommended to be screened pan-ethnically,
yet the mutations most commonly assayed were determined
because of their prevalence in the Caucasian population. A
population-based screening program ideally serves all sub-
groups well. Thus, equitable application of ECS may actually
necessitate an NGS approach, at least for a subset of genes.Diseases screened
Professional society statements do not specify diseases that
should be included or excluded in an expanded carrier
screening panel.26,27 This has led to variability in current
commercially available screening panels, which may lead to
inefﬁciencies or confusion among providers and patients. A
committee issuing guidelines from the European Society of
Human Genetics analyzed the diseases tested by four labo-
ratories, ranging from 74 to 210 diseases, and found that only
29 were in common.28 Within these diseases, differences in
methods and mutations assayed also contribute to the
current lack of uniformity in offering expanded screening.
Existing professional statements stipulate that diseases
warrant inclusion particularly when they exhibit cognitive
disability or adverse impact on quality of life. Diseases that
would be tested by, and especially alter management based
on results of, prenatal diagnostic methods ﬁt these criteria.While no organization suggests that any speciﬁc diseases be
deﬁnitively excluded from a panel, they do suggest that those
with mild phenotypes, adult-onset presentation or low pen-
etrance be made optional.
At the heart of these criteria are measures of severity, though
this is easily subject to individual discretion. To address the
pitfalls of incorporating severity into development of broad
screening programs, Lazarin et al.36 developed a classiﬁcation
algorithm that assigns severity (profound—4, severe—3, moder-
ate—2, and mild—1) based on discrete disease characteristics.
Based on the ACMG’s assessment of severity in diseases consid-
ered for newborn screening, this scale enables an objective
assessment of an individual laboratory’s screening panel, and a
means to facilitate discussions of ECS panels with patients.
In contrast with the rationale for single disease guidelines,
criteria such as carrier and disease frequency and clinical
sensitivity of available testing are no longer stipulated in the
expanded screening statements. They are mentioned only
insomuch as to ensure that providers and laboratories are aware
of the need to communicate a priori and residual risk data.
Severity is often determined by the deleterious effects of the
mutations in a gene. The history of cystic ﬁbrosis carrier
screening and the broad phenotypes associated with this
disorder have revealed the challenges of classifying these gene
effects.37 In particular, as NGS approaches become more
common, variant interpretation in reproductive carrier screen-
ing will need as much attention and resource usage as in other
areas of clinical genetics. Since personal decisions may result
from carrier screening results, often without the ability to
fully observe fetal effects, transparent methods of variant
classiﬁcation are of utmost importance.38 Variants of uncer-
tain signiﬁcance add complexity to patient counseling. Cur-
rently most laboratories performing NGS for the dedicated
purpose of carrier screening do not reveal these variants in
result reports, as is recommended by the joint. Points to
Consider statement.27 However, this practice may not be
uniform, and variants of uncertain signiﬁcance may be
revealed if ordering a gene sequence analysis that a laboratory
designed for diagnostic, rather than screening, purposes.
Therefore, providers ordering ECS using NGS methods should
be cognizant of a laboratory’s variant classiﬁcation and report-
ing protocols.Provider perspectives
Practices and attitudes amongst physicians, genetic counse-
lors, and other providers are likely still evolving with ECS. To
date, perspectives have been positive, though accompanied
by some concerns regarding implementation. There is also a
seeming dichotomy between screening preferences for one-
self and for one’s patients.
Ready et al.39 surveyed obstetricians, reproductive endo-
crinologists, nurses, and other health care providers, assess-
ing basic genetic and genetic screening knowledge.
Respondents were generally accurate in their responses to
questions about recessive inheritance, consistent with
other similar data.40 Regarding ECS speciﬁcally, 78% person-
ally preferred being screened for more, rather than less,
disorders. Personal interest was likewise high among genetic
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themselves.41
Physicians and genetic counselors also express concern
regarding practical implementation of ECS, including pre-
and post-test education and counseling. ACOG Fellows sur-
veyed expressed discomfort having both pre- and post-test
discussions about ECS and over half stated that patients
should receive pre-test counseling from a genetic counselor.42
Nearly 40% of genetic counselors also believed that pre-test
counseling should be administered by a GC, though other
alternatives were acceptable to the remainder.41 A focus
group of genetic specialists agreed that counseling before
and after testing was important, and also expected that
reproductive health care providers would be generally com-
fortable with this, since there is similarity between ECS and
screening for many disorders in the Ashkenazi Jewish
population.43
These studies indicate general agreement regarding han-
dling of ECS results—genetic counseling is indicated in cases
of positive results (either one partner, or both partners for the
same condition), but negative results do not typically neces-
sitate formal counseling. Of note, several laboratories that
perform ECS also provide post-test genetic counseling serv-
ices, typically by telephone.
While the provider surveys to date have indicated general
acceptance and strong personal interest for ECS, actual
utilization lags signiﬁcantly. Only 15% of ACOG Fellows
offered ECS to all of their patients and 77% indicated that
ECS should only be offered based on family history, race/
ethnicity, or as recommended by ACOG.42 This pattern was
also found among genetic counselors, in which 80% would
personally elect ECS for themselves, yet very few were
offering it to all of their patients.41 The discrepancies
observed here merit further investigation, and may originate
from the practical implications of the counseling perspectives
discussed above.Conclusion
Expanded carrier screening is a new approach, with much to
be settled including diseases that should be tested, optimal
pre- and post-test counseling, and impact on clinical and
public health outcomes. Nonetheless, it is becoming more
common.
We estimate that over 200,000 individuals have undergone
ECS in 2015. This is a small percentage of the four million
annual pregnancies in the US, but is more considerable in the
context of the population that currently has carrier screening
of any kind.
Current literature and personal observation point to the
need for research on the following speciﬁc topics:1. Cost-effectiveness in comparison to traditional carrier
screening and no carrier screening at all, for public health
effect consideration.2. Patient and provider perspectives on diseases to be
included or excluded, or other means of establishing
greater uniformity among different laboratory panels.3. Accurate carrier frequencies and test sensitivity data for
each disease being screened, in addition to more robust
variant classiﬁcations.4. Methods of pre- and post-test counseling that balance the
increased load of genetic information with already
strained genetics specialist resources.5. Education models for increasing awareness and under-
standing among non-genetics providers and the general
public.6. Clinical outcomes among at-risk couples.
7. Patient satisfaction and experience before, during, and
after undergoing ECS, in comparison to traditional carrier
screening and no carrier screening at all.While further data on these topics are developed, ECS
continues to be offered and performed in the US. Outside
the US, whether and how to integrate ECS into their health
care systems is a new topic, which may raise similar and
unique considerations as well.30,44
Here, an overview of ECS is presented. Examination of the
criteria historically used to design screening programs
reveals limitations due to increasing population diversity
and little disease coverage in relation to total available
opportunity. Initial laboratory data has established that test-
ing is reliably accurate and reinforces the presumptions that
many people carry diseases for which they are not being
screened. Current provider perspectives generally accept the
utility of ECS, while also revealing concerns about genetic
counseling and the limitations of current genetics knowledge.
Finally, many professional organizations have issued state-
ments acknowledging the described beneﬁts, while still with-
holding an opinion for ECS over traditional screening, due to
the concerns described. Undoubtedly, this ﬁeld will continue
to evolve, with substantial new developments expected in
coming years.Acknowledgments
The authors thank Carlo Artieri, PhD, for his contributions to
article review and editing.
r e f e r e n c e s
1. American College of Obstetricians and Gynecologists. Com-
mittee opinion no. 325: update on carrier screening for cystic
ﬁbrosis. Obstet Gynecol. 2005;106(6):1465–1468.
2. Watson MS, Cutting GR, Desnick RJ, et al. Cystic ﬁbrosis
population carrier screening: 2004 revision of American Col-
lege of Medical Genetics mutation panel. Genet Med. 2004;6
(5):387–391.
3. Prior TW. Professional practice and guidelines committee.
Carrier screening for spinal muscular atrophy. Genet Med.
2008;10(11):840–842.
4. American College of Obstetricians and Gynecologists & Amer-
ican College of Medical Genetics. Preconception and Prenatal
Carrier Screening for Cystic Fibrosis. Clinical and Laboratory Guide-
lines. Washington, DC: American College of Obstetricians and
Gynecologists; 2001.
S E M I N A R S I N P E R I N A T O L O G Y 4 0 ( 2 0 1 6 ) 2 9 – 3 4345. Ross LF. A re-examination of the use of ethnicity in prenatal
carrier testing. Am J Med Genet A. 2012;158A(1):19–23.
6. Shafer FE, Lorey F, Cunningham GC, et al. Newborn screening
for sickle cell disease: 4 years of experience from California’s
newborn screening program. J Pedatr Hematol Oncol. 1996;18(1):
36–41.
7. U.S. Census Bureau. Statistical Abstract of the United States:
2011, 130th ed. Washington, DC; 2010.
8. Sheskin I, Dashesfsky A. Jewish Population of the United States.
Storrs, CT: University of Connecticut; 2010;78.
9. Bley AE, Giannikopoulos OA, Hayden D, et al. Natural history
of infantile (GM2) gangliosidosis. Pediatrics. 2011;128(5):
e1233–e1241.
10. American College of Obstetricians and Gynecologists. Practice
bulletin no. 78: hemoglobinopathies in pregnancy. Obstet
Gynecol. 2007;109(1):229–237.
11. American College of Obstetricians and Gynecologists. Com-
mittee opinion no. 442: preconception and prenatal carrier
screening for genetic diseases in individuals of Eastern Euro-
pean Jewish descent. Obstet Gynecol. 2009;14:950–959.
12. Gross SJ, Pletcher BA, Monaghan KG. Professional practice
and guidelines committee. Carrier screening in individuals of
Ashkenazi Jewish descent. Genet Med. 2008;10(4):54–56.
13. Scott SA, Edelmann L, Liu L, Luo M, Desnick RJ, Kornreich R.
Experience with carrier screening and prenatal diagnosis for
16 Ashkenazi Jewish genetic diseases. Hum Mutat. 2010;31(11):
1240–1250.
14. Shao Y, Liu S, Grinzaid K. Evaluation of a two-year Jewish
genetic disease screening program in Atlanta: insight into
community genetic screening approaches. J Community Genet.
2015;6(2):137–145.
15. Hoffman JD, Park JJ, Schreiber-Agus N, et al. The Ashkenazi
Jewish carrier screening panel: evolution, status quo, and
disparities. Prenat Diagn. 2014;34(12):1161–1167.
16. Kingsmore S. Comprehensive carrier screening and molecular
diagnostic testing for recessive childhood diseases. PLoS Curr.
2012;4:e4f9877ab8ffa9.
17. Srinivasan BS, Evans EA, Flannick J, et al. A universal carrier
test for the long tail of Mendelian disease. Reprod Biomed
Online. 2010;21(4):537–551.
18. Castellani C, Picci L, Tridello G. Cystic ﬁbrosis carrier screen-
ing effects on birth prevalence and newborn screening. Genet
Med. 2015. http://dx.doi.org/10.1038/gim.2015.68.
19. Hale J. Newborn screening showing decreasing incidence of
cystic ﬁbrosis. N Engl J Med. 2008;358(9):973–974.
20. Haque IS, Lazarin GA, Raia M, Bellerose H, Evans EA,
Goldberg J. Expanded carrier screening of 322,484 individuals:
the case for going beyond cystic ﬁbrosis. Eur J Hum Genet.
2015;23:S1.
21. N. Cheschier, ACOG Committee on Practice Bulletins. ACOG
practice bulletin. Neural tube defects. Clinical management
guidelines for obstetricians–gynecologists. Number 44, July
2003. Int J Gynaecol Obstet. 2003;83(1):123–133.
22. ACOG Committee on Practice Bulletins. ACOG practice bulle-
tin no. 77: screening for fetal chromosomal abnormalities.
Obstet Gynecol. 2007;109(1):217–227.
23. Wilcken B. More on medium-chain acyl-Coenzyme A dehy-
drogenase deﬁciency in a neonate. N Engl J Med. 2008;358
(6):647.
24. Bailey DB, Raspa M, Bishop E, Holiday D. No change in the age
of diagnosis for fragile X syndrome: ﬁndings from a national
parent survey. Pediatrics. 2009;124(2):527–533.
25. Browning MF, Levy HL, Wilkins-Haug LE, Larson C, Shih VE.
Fetal fatty acid oxidation defects and maternal liver disease
in pregnancy. Obstet Gynecol. 2006;107(1):115–120.
26. Grody WW, Thompson BH, Gregg AR, et al. ACMG position
statement on prenatal/preconception expanded carrier
screening. Genet Med. 2013;15(6):482–483.27. Edwards JG, Feldman G, Goldberg J, et al. Expanded carrier
screening in reproductive medicine—points to consider.
Obstet Gynecol. 2015;125(3):653–662.
28. Elias S, Annas GJ. Generic consent for genetic screening.
N Engl J Med. 1994;330(22):1611–1613.
29. Reeves A, Trepanier A. Comparison of informed consent
preferences for multiplex genetic carrier screening among a
diverse population. J Genet Counsel. 2015. http://dx.doi.org/
10.1007/s10897-015-9854-4.
30. Henneman L, Borry P, Chokoshvili D, et al. Responsible
implementation of expanded carrier screening: Summary
and recommendations of the European Society of Human
Genetics. Eur J Hum Genet. 2015. [in press].
31. Klugman S, Schreiber-Agus N, Nazareth S, Evans EA. Detec-
tion of carriers in the Ashkenazi Jewish population: an
objective comparison of high-throughput genotyping versus
gene-by-gene testing. Genet Test Mol Biomarkers. 2013;17(10):
763–767.
32. Bell CJ, Dinwiddie DL, Miller NA, et al. Carrier testing for
severe childhood recessive diseases by next-generation
sequencing. Sci Transl Med. 2011;3(65):65ra4.
33. Lazarin GA, Haque IS, Nazareth S, et al. An empirical estimate
of carrier frequencies for 400þ causal Mendelian variants:
results from an ethnically diverse clinical sample of 23,453
individuals. Genet Med. 2013;15(3):178–186.
34. Hallam S, Nelson H, Greger V, et al. Validation for clinical use
of, and initial clinical experience with, a novel approach to
population-based carrier screening using high-throughput,
next-generation DNA sequencing. J Mol Diagn. 2014;16(2):
180–189.
35. Lim RM, Silver AJ, Silver MJ, et al. Targeted mutation screen-
ing panels expose systematic population bias in detection of
cystic ﬁbrosis risk. Genet Med. 2015. http://dx.doi.org/10.1038/
gim.2015.52.
36. Lazarin GA, Hawthorne F, Collins NS, et al. Systematic
classiﬁcation of disease severity for evaluation of expanded
carrier screening panels. PLoS One. 2014;9(12):e114391.
37. Grody WW, Cutting GR, Watson MS. The cystic ﬁbrosis
mutation “arms race”: when less is more. Genet Med. 2007;9
(11):739–744.
38. Perrault-Micale C, Davie J, Breton B, Hallam S, Greger VA.
Rigorous approach for selection of optimal variant sets for
carrier screening with demonstration of clinical utility. Mol
Genet Genomics Med. 2015;3(4):363–373. http://dx.doi.org/
10.1002/mgg3.148.
39. Ready K, Haque IS, Srinivasan BS, Marshall JR. Knowledge and
attitudes regarding expanded genetic carrier screening
among women’s healthcare providers. Fert Ster. 2012;97(2):
407–413.
40. Darcy D, Tian L, Taylor J, Schrijver I. Cystic ﬁbrosis carrier
screening in obstetric clinical practice: knowledge, practices,
and barriers, a decade after publication of screening guide-
lines. Genet Test Mol Biomarkers. 2011;15(7-8):517–523.
41. Lazarin GA, Detweiler S, Nazareth SB, Ashkinadze E. Genetic
counselors’ perspectives and practices regarding expanded
carrier screening after initial clinical availability. J Genet
Couns. 2015 http://dx.doi.org/10.1007/s10897-015-9881-1.
42. Benn P, Chapman AR, Erickson K, et al. Obstetricians’ and
gynecologists’ practice and opinions of expanded carrier
testing and non-invasive prenatal testing. Prenat Diagn.
2014;34(2):145–152.
43. Cho D, McGowan ML, Metcalfe J, Sharp RR. Expanded carrier
screening in reproductive healthcare: perspectives from
genetics professionals. Hum Reprod. 2013;28(6):1725–1730.
44. Holtkamp KCA, van Maarle MC, Schouten MJE, et al. Do
people from the Jewish community prefer ancestry-based or
pan-ethnic expanded carrier screening. Eur J Hum Genet. 2015.
http://dx.doi.org/10.1038/ejhg.2015.97.
